497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial

Keyphrases

• COVID-19 100%
• Research Support 100%
• Tolerability 100%
• Sotrovimab 100%
• Intravenous Dose 60%
• AstraZeneca 40%
• Autoimmune Disease 40%
• Transplant Recipients 40%
• Dialysis 40%
• Honorarium 40%
• Hospital Admission 20%
• Early Treatment 20%
• Test Evaluation 20%
• Response to Vaccination 20%
• Placebo 20%
• Immunosuppression 20%
• Immunodeficiency 20%
• Patient Demographics 20%
• Monoclonal Antibody 20%
• Fever 20%
• Infusion Reaction 20%
• Headache 20%
• Clinically Significant 20%
• Dizziness 20%
• Laboratory Parameters 20%
• Oncologic 20%
• Immune Deficiency 20%
• Prophylactic Treatment 20%
• Pre-exposure 20%
• Dual Action 20%
• Vulnerable People 20%
• Biochemical Markers 20%
• Treatment Information 20%
• Severe Adverse Events 20%
• Common Symptoms 20%
• EudraCT 20%
• Gilead 20%
• Pre-exposure Prophylaxis (PrEP) 20%
• Hematological Markers 20%
• Platform Trials 20%
• Blind Analysis 20%
• Vulnerable Patient Populations 20%
• SARS-CoV-2 Infection 20%
• SARS-CoV-2 Vaccine 20%
• Oncological Diseases 20%
• Biochemical Blood Test 20%
• Grade Two 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Glycogen Synthase Kinase 100%
• SARS Coronavirus 100%
• Autoimmune Disease 50%
• Immune Deficiency 50%
• Infection 25%
• Adverse Event 25%
• Placebo 25%
• Headache 25%
• Monoclonal Antibody 25%
• Biochemical Marker 25%
• Inosine Phosphate 25%
• Rigor 25%
• Dizziness 25%
• COVID-19 Vaccine 25%
• Infusion Related Reaction 25%
• Diseases 25%